Register Login

Pieris Pharmaceuticals Inc. (PIRS)

(70% Positive) PALVELLA THERAPEUTICS, INC. (PIRS) Announces Enrollment Update for Data Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Dec. 15, 2025, 11:09 a.m.

    📋 PALVELLA THERAPEUTICS, INC. (PIRS) - Clinical Trial Update

    Filing Date: 2025-12-15

    Accepted: 2025-12-15 06:05:43

    Event Type: Clinical Trial Update

    Event Details:

    Pieris Pharmaceuticals Inc. (PIRS) Announces Clinical Trial Update Pieris Pharmaceuticals Inc. (PIRS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Data, contained
    • Diseases/Conditions: some cases
    • Clinical Stage: Phase 2, clinical trial
    • Collaboration: Palvella Therapeutics, Inc.
    • Updated Timeline: December 15, 2025 2

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Pieris Pharmaceuticals Inc.
    • CIK: 0001583648
    • Ticker Symbol: PIRS
    • Period End Date: 2025-12-15
    • Document Type: 8-K

Search

News categories